TheStreet home
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTCRYPTOMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTERTECHNOLOGY
Search

LATEST NEWS

Small-Cap Stocks Are Doing Something They Haven't Done Consistently in 3 Years
OPINION

Small-Cap Stocks Are Doing Something They Haven't Done Consistently in 3 Years

PRESS RELEASES

CCXI INVESTOR ALERT: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against ChemoCentryx, Inc.

PRESS RELEASES

CCXI CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces A Securities Fraud Class Action Lawsuit Filed Against ChemoCentryx, Inc.

PRESS RELEASES

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces That A Class Action Lawsuit Has Been Filed Against ChemoCentryx, Inc. And Encourages Investors To Contact The Firm

PRESS RELEASES

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages ChemoCentryx, Inc. Investors With Losses In Excess Of $100K To Secure Counsel Before Important Deadline - CCXI

PRESS RELEASES

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of ChemoCentryx, Inc. - CCXI

PRESS RELEASES

Ademi LLP Investigates Claims Of Securities Fraud Against ChemoCentryx Inc.

PRESS RELEASES

INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against ChemoCentryx, Inc. And Encourages Investors With Losses To Contact The Firm

PRESS RELEASES

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages ChemoCentryx (CCXI) Investors With Losses To Contact Its Attorneys Now, FDA Briefing Document Raises Serious Questions, Firm Investigating Possible Securities Law Violations

PRESS RELEASES

INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against ChemoCentryx, Inc. And Encourages Investors With Losses To Contact The Firm

PRESS RELEASES

ChemoCentryx To Hold First Quarter 2021 Financial Results Conference Call On Thursday, April 29, 2021

PRESS RELEASES

ChemoCentryx's Oral PD-L1 Inhibitor, CCX559, Featured In Poster Presentation At The 2021 American Association For Cancer Research (AACR) Annual Meeting

PRESS RELEASES

ChemoCentryx To Host Virtual R&D Day On April 14, 2021

PRESS RELEASES

ChemoCentryx Announces Appointment Of Susan M. Kanaya To Board Of Directors

PRESS RELEASES

ChemoCentryx To Present At Two Upcoming Investor Conferences

PRESS RELEASES

ChemoCentryx Appoints Tausif ('Tosh') Butt As Executive Vice President And Chief Operating Officer

PRESS RELEASES

ChemoCentryx To Hold Fourth Quarter And Full Year 2020 Financial Results Conference Call on Monday, March 1, 2021

PRESS RELEASES

ChemoCentryx Announces Publication In The New England Journal Of Medicine Of Results Of The Pivotal Phase III ADVOCATE Trial Of Avacopan For The Treatment Of ANCA-Associated Vasculitis

PRESS RELEASES

ChemoCentryx To Participate In Two Upcoming Investor Conferences

PRESS RELEASES

ChemoCentryx To Present At Two Upcoming Investor Conferences

PRESS RELEASES

ChemoCentryx Announces Plenary Session At ACR Convergence 2020 To Highlight Findings Of ADVOCATE Phase III Trial In ANCA-Associated Vasculitis

PRESS RELEASES

ChemoCentryx To Hold Third Quarter 2020 Financial Results Conference Call On Monday, November 9, 2020

PRESS RELEASES

ChemoCentryx Announces FDA Acceptance Of The Avacopan New Drug Application (NDA) For The Treatment Of ANCA-Associated Vasculitis

PRESS RELEASES

ChemoCentryx To Present At The H.C. Wainwright 22nd Annual Global Investment Conference

PRESS RELEASES

ChemoCentryx To Present At Two Upcoming Investor Conferences